Interpace Biosciences Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Interpace Biosciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Interpace Biosciences stock.
View analyst ratings for Interpace Biosciences or view top-rated stocks.

Wall Street analysts have given Interpace Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Interpace Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Interpace Biosciences is scheduled to release its next quarterly earnings announcement on Monday, October 18th 2021.
View our earnings forecast for Interpace Biosciences.

Interpace Biosciences, Inc. (NASDAQ:IDXG) issued its quarterly earnings data on Tuesday, May, 11th. The business services provider reported ($1.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.43) by $0.41. The business services provider had revenue of $9.83 million for the quarter, compared to analysts' expectations of $9 million.
View Interpace Biosciences' earnings history.

Interpace Biosciences updated its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $42 million-$44 million, compared to the consensus revenue estimate of $39.60 million.

2 brokers have issued twelve-month price targets for Interpace Biosciences' shares. Their forecasts range from $7.00 to $11.00. On average, they anticipate Interpace Biosciences' share price to reach $9.00 in the next year. This suggests that the stock has a possible downside of 11.4%.
View analysts' price targets for Interpace Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Interpace Biosciences include Laboratory Co. of America (LH), Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), Chemed (CHE), LHC Group (LHCG), R1 RCM (RCM), AMN Healthcare Services (AMN), MEDNAX (MD), CorVel (CRVL), Tivity Health (TVTY) and Cross Country Healthcare (CCRN).
View all of IDXG's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Interpace Biosciences investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Histogenics (HSGX), Johnson & Johnson (JNJ), SCYNEXIS (SCYX), Cisco Systems (CSCO), Trevena (TRVN) and TherapeuticsMD (TXMD).

Interpace Biosciences trades on the NASDAQ under the ticker symbol "IDXG."

Interpace Biosciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include HRT Financial LP (0.27%).
View institutional ownership trends for Interpace Biosciences.

IDXG stock was purchased by a variety of institutional investors in the last quarter, including HRT Financial LP.
View insider buying and selling activity for Interpace Biosciences or or view top insider-buying stocks.

One share of IDXG stock can currently be purchased for approximately $10.16.

Interpace Biosciences has a market capitalization of $41.76 million and generates $32.40 million in revenue each year. The business services provider earns $-26,450,000.00 in net income (profit) each year or ($7.26) on an earnings per share basis.

Interpace Biosciences employs 152 workers across the globe.

The official website for Interpace Biosciences is www.interpace.com.

Interpace Biosciences is headquartered at MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054.

Interpace Biosciences' mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]